cambiogenplasmid

Cambiogenplasmid (marketed under the brand name Neovasculgen) is a first-in-class non-viral plasmid gene therapy developed by the Human Stem Cells Institute (now Artgen Biotech) for the treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI). It consists of a supercoiled plasmid DNA vector encoding the 165-amino-acid isoform of human vascular endothelial growth factor (VEGF165) under the control of a cytomegalovirus (CMV) promoter. Following local intramuscular injection, the plasmid is transiently expressed in ischemic tissues, producing and secreting VEGF165. This protein binds to and activates VEGF receptors (primarily VEGFR2) on endothelial cells, stimulating therapeutic angiogenesis (the growth of new blood vessels) to bypass arterial blockages and restore blood perfusion. Cambiogenplasmid was approved in Russia in 2011.

Brand names

Neovasculgen

Other names

cambiogeneplasmidpVEGF165pVEGF-165pVEGF 165plasmid VEGF165plasmid-VEGF165plasmid-VEGF-165plasmid-VEGF 165